Trials / Not Yet Recruiting
Not Yet RecruitingNCT06824454
Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary goal is to determine if Dipyridamole can improve serum phosphate levels and reduce the need for phosphate supplementation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dipyridamole 75 MG | Dipyridamole administered three times daily when serum phosphorus levels fall below 4 mg/dL. The drug is used off-label for this study to manage hypophosphatemia in kidney transplant recipients. |
Timeline
- Start date
- 2025-03-01
- Primary completion
- 2026-03-01
- Completion
- 2026-03-01
- First posted
- 2025-02-13
- Last updated
- 2025-02-13
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06824454. Inclusion in this directory is not an endorsement.